Braveheart Bio, Inc. — Form SCHEDULE 13D/A
Filed September 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Genesis GP LLC filed Amendment No. 1 to Schedule 13D on September 10, 2026, regarding common stock of Braveheart Bio, Inc. The document is a joint filing agreement establishing shared responsibility for accuracy and timeliness of the amended disclosure. No specific shareholding percentages, share counts, or dollar amounts are disclosed in this excerpt.
Why this rating
Procedural amendment filing; joint filing agreement is administrative boilerplate. No change in ownership stake, transaction size, or business terms disclosed here.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.